Latest Data in FSGS and IgAN

Expert faculty, Dr. Richard Lafayette, explores clinical trial data coming out of a recent nephrology meeting, and provides learners with up-to-date knowledge on focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). This brief interview-style video offers insights into the patient burden of chronic kidney disease, advances in understanding the pathophysiology, and emerging approaches to treatment for this patient population. Dr. Lafayette discusses current barriers, emerging evidence, and strategies to incorporate advances.

Focal segmental glomerulosclerosis and IgAN are glomerular disorders that contribute to kidney failure and the need for dialysis and/or transplant. Although both are associated with kidney injury, they have different pathophysiologies, along with considerable disease heterogeneity. There are no currently approved therapies and the management of FSGS and IgAN is challenging. Recent research has identified potential therapeutic targets for individuals with these progressive kidney diseases and there are a number of ongoing clinical trials. This education brings clinicians up-to-date on potential treatment targets and agents in the pipeline for progressive kidney disease.